Nurix Therapeutics (NRIX) Study update summary

Strategic Collaboration Overview

• A global partnership was announced to co-develop and commercialize bexobrutideg (Bexdeg), an oral BTK degrader, targeting oncology, immunology, and neurology indications, leveraging expertise in targeted protein degradation and B-cell therapies.

• Roche and Nurix will co-develop Bexdeg, sharing development costs (Nurix 40%, Roche 60%) and U.S. profits 50/50, with Roche handling ex-U.S. commercialization and royalties.

• Nurix receives $700 million upfront, with total potential payments up to $2.3 billion based on milestones, plus significant downstream economics.

• The collaboration leverages Roche’s global clinical, regulatory, and commercial infrastructure to accelerate Bexdeg’s development and reach.

• The deal is positioned as one of the largest for a degrader drug, reflecting high confidence in Bexdeg’s potential.

Clinical and Scientific Rationale

• Bexdeg is a brain-penetrant, highly selective oral BTK degrader that eliminates both enzymatic and scaffolding functions of BTK, acting catalytically with high potency and selectivity.

• Demonstrated 83% objective response rate and median progression-free survival of 22.1 months in heavily pretreated CLL patients, including those with resistance mutations and CNS involvement.

• Durable disease control observed across high-risk and hard-to-treat CLL subgroups, with activity against wildtype and BTK inhibitor-resistant mutations.

• Demonstrated ability to cross the blood-brain barrier, supporting potential in CNS lymphoma and MS.

• Offers potential advantages over BTK inhibitors, such as improved efficacy, safety, and convenience, including lower systemic exposure and broad mutation coverage.

Development Plan and Expansion

• Joint development plan targets CLL, NHL, CSU, and MS, with studies as monotherapy and in combination with Roche’s portfolio drugs.

• Key ongoing and planned studies include DAYBreak CLL-201 (accelerated approval), phase III DAYBreak CLL-306, and a phase I-B/II basket combination study.

• Expansion into CSU and MS is supported by Bexdeg’s potent BTK degradation in relevant cell types and tissues, with phase II trials actively being planned.

• Multiple phase 2 and 3 studies are planned or ongoing in B-cell malignancies and new indications, aiming for rapid progression to phase III.

• The collaboration aims to establish Bexdeg as a backbone therapy across BTK-mediated diseases.